Aurinia Pharmaceuticals Inc. (AUPH) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aurinia Pharmaceuticals I... (AUPH)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.53

-0.24 (-3.09%)

At close: Jan 14, 2025, 3:59 PM

7.56

0.41%

After-hours Jan 14, 2025, 07:57 PM EST

undefined% (undefined)

Bid	7.3
Market Cap	1.08B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.15
PE Ratio (ttm)	-50.2
Forward PE	n/a
Analyst	Buy

Ask	10.17
Volume	1,418,710
Avg. Volume (20D)	1,385,139
Open	7.85
Previous Close	7.77
Day's Range	7.52 - 7.94
52-Week Range	4.71 - 10.67
Beta	undefined

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 3, 2014

Employees 300

Stock Exchange NASDAQ

Ticker Symbol AUPH

Website https://www.auriniapharma.com

Analyst Forecast

According to 3 analyst ratings, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 32.80% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Aurinia Pharmaceuticals Inc. is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $59.94M, reflecting a 32.92% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.

Why Price Moved

2 months ago · Source

+10.9%

Aurinia Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

4 months ago · Source

+0.77%

Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.

News

1 month ago · 247wallst.com

Insiders Are Loving These 6 Stocks Right Now

The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.

1 month ago · businesswire.com

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.

2 months ago · businesswire.com

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual Ame...

2 months ago · businesswire.com

Aurinia to Participate in Jefferies London Healthcare Conference

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies London Healthcare Conference.

2 months ago · seekingalpha.com

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impres...

2 months ago · seekingalpha.com

Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf ...

2 months ago · zacks.com

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.09 per share a year ago.

2 months ago · businesswire.com

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth.

2 months ago · businesswire.com

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months ended...

2 months ago · businesswire.com

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024.